Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed prostate cancer
• Low-risk for progression, as evidenced by all of the following:
• * Tumor stage ≤ T2a
• * PSA ≤ 10 ng/mL
• * Gleason score ≤ 7
• Patients informed of treatment options and has already chosen to undergo active surveillance
• * No decision to stop active surveillance
• No node-positive or metastatic disease
• PATIENT CHARACTERISTICS:
• Willing to undergo MRI
• Willing to undergo prostate biopsy
• No contraindications to MRI that include, but not limited to, any of the following:
• * Claustrophobia
• * Anxiety
• * Presence of metal or shrapnel in the body
• * Pacemakers
• * Old tattoos with metal-based dye material
• No contraindication to prostate biopsy
• No medical conditions, as deemed by the PI or associates, that would prevent or limit the patient participation on the protocol that include, but not limited to, any of the following:
• * Severe coagulopathy
• * History of severe bleeding
• * Severe coronary artery disease
• * Other comorbid conditions that limit life expectancy to less than 2 years
• PRIOR CONCURRENT THERAPY:
• No hormone therapy within the past year
• No prior pelvic radiotherapy
• No prior prostate resection including transurethral resection of prostate
• Concurrent participation in other clinical studies (e.g., vitamin D, selenium) allowed provided active surveillance is continued